A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Longboard Pharmaceuticals
- Study ID
- NCT06660394
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Dravet Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- LP352 — DRUGLP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
- Placebo — DRUGParticipants will be administered with matching placebo orally or through G-tube/ PEG tube
Study Details
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Key Dates
- First listed
- Oct 28, 2024
- Start date
- Sep 25, 2024
- Status verified
- Aug 2026
- Primary completion
- Aug 21, 2026
- Completion
- Oct 2, 2026
Study Design
- Enrollment
- 104 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LP352Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 2 - Visit 5), followed by maintenance period (Visit 5 - Visit 8) and then taper/down titration period.
- Placebo Comparator: PlaceboPlacebo for LP352
Primary Outcome Measure
Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline [ Time Frame: Baseline and up to 15 Weeks ]
Central Contacts
- Email contact via H. Lundbeck A/S+45 36301311
Locations (25)
Find similar trials in Little Rock, AR
By research site
Arkansas Children's Hospital - Cardiology Clinic· Little Rock, ARChildren's Hospital Los Angeles - PIN· Los Angeles, CADavid Geffen School of Medicine at UCLA· Los Angeles, CAThe Stanford Division of Child Neurology· Palo Alto, CAUCSF Benioff Children's Hospitals - San Francisco· San Francisco, CAChildren's Hospital Colorado.· Aurora, CO
Related Studies
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromePHASE3 · Recruiting · Epygenix · Birmingham, Alabama
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromePHASE1/PHASE2 · Recruiting · Encoded Therapeutics · San Francisco, California
- GABA Biomarkers in Dravet SyndromeRecruiting · Cook Children's Health Care System · Fort Worth, Texas
- A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePHASE3 · Recruiting · Stoke Therapeutics, Inc · Phoenix, Arizona